何毅豪, 汪颖舒, 杜瑶瑶, 张彤, 王冰. 网络药理学整合巨噬细胞差异基因揭示广藿香油对炎症性肠病的治疗机制J. 药学学报, 2021,56(12): 3473-3483. doi: 10.16438/j.0513-4870.2021-0218
引用本文: 何毅豪, 汪颖舒, 杜瑶瑶, 张彤, 王冰. 网络药理学整合巨噬细胞差异基因揭示广藿香油对炎症性肠病的治疗机制J. 药学学报, 2021,56(12): 3473-3483. doi: 10.16438/j.0513-4870.2021-0218
HE Yi-hao, WANG Ying-shu, DU Yao-yao, ZHANG Tong, WANG Bing. Network pharmacology integrates the differential genes of macrophages to explain the mechanism of patchouli oil treating IBDJ. Acta Pharmaceutica Sinica, 2021,56(12): 3473-3483. doi: 10.16438/j.0513-4870.2021-0218
Citation: HE Yi-hao, WANG Ying-shu, DU Yao-yao, ZHANG Tong, WANG Bing. Network pharmacology integrates the differential genes of macrophages to explain the mechanism of patchouli oil treating IBDJ. Acta Pharmaceutica Sinica, 2021,56(12): 3473-3483. doi: 10.16438/j.0513-4870.2021-0218

网络药理学整合巨噬细胞差异基因揭示广藿香油对炎症性肠病的治疗机制

Network pharmacology integrates the differential genes of macrophages to explain the mechanism of patchouli oil treating IBD

  • 摘要: 基于网络药理学和巨噬细胞差异表达基因探究广藿香油治疗炎症性肠病(inflammatory bowel disease,IBD)的作用机制。利用气质联用技术(GC-MS)检测广藿香油的化学成分,通过TCMSP和Swiss Target Prediction平台收集活性成分的靶点,检索DrugBank、GeneCards、OMIM、PharmGkb和TTD数据库筛选治疗IBD的靶标。合并取交集靶点,运用Cytoscape软件构建"成分-交集靶点"网络,并联合String平台绘制PPI网络,在Metascape平台将交集靶点进行GO和KEGG富集分析,应用AutoDock Vina分子对接,对分析结果进行验证。下载巨噬细胞芯片数据,借用R软件获得差异基因,DAVID平台进行差异基因KEGG通路富集分析。采用实时荧光定量PCR对筛出的主要成分在体外细胞模型进行验证。广藿香油14个主要成分对应112个靶点,交集得到97个广藿香油治疗IBD共同靶点。GO富集分析得到53个条目。KEGG富集分析得到18个条目,涉及cAMP信号通路、Notch信号通路、黏附连接以及Th17细胞分化等信号通路。分子对接表明,广藿香油中筛选出的活性成分与靶点有较好的结合活性。差异表达基因富集到Toll样受体、Jak-STAT和NF-κB信号通路等炎症相关通路。q-PCR实验证明,广藿香油、广藿香醇和广藿香酮能降低NCM460人正常结肠上皮细胞炎症模型中细胞因子(TNF-α、IL-1β、IL-6和IL-23)和上调紧密连接蛋白(occludin和claudin-1)的mRNA水平。广藿香醇能显著降低脂多糖诱导的RAW264.7巨噬细胞TNF-α、IL-6和IL-1β炎症因子水平。本文揭示了广藿香油的多成分、多靶点、多通路的特征,且证实广藿香油及主要成分在体外炎症细胞模型的抗炎效果和保护肠上皮屏障完整性功能,为进一步阐明广藿香油治疗IBD的机制提供理论依据。

     

    Abstract: We explored the mechanism of patchouli oil in the treatment of inflammatory bowel disease (IBD) based on network pharmacology and differentially expressed genes in macrophages. The chemical composition of patchouli oil was detected by GC-MS, targets for active components were collected through TCMSP and Swiss Target Prediction platform, and targets for treatment of IBD were retrieved from DrugBank, GeneCards, OMIM, PharmGkb, and TTD databases. The intersection targets were merged, Cytoscape software was used to construct the "component-to-intersection target" network, and protein-protein interaction (PPI) network was drawn with String platform. The intersection targets were enriched for GO and KEGG enrichment analysis on Metascape platform, and the molecular docking of AutoDock Vina was used to verify the analysis results. The macrophage chip data was downloaded, and the differential genes were obtained by using R software. KEGG signaling pathway analysis of differentially expressed genes were performed by DAVID platform. Real-time fluorescence quantitative PCR was used to verify the screened components in the cell model in vitro. The 14 main components of patchouli oil corresponded to 112 targets, and the intersection obtained 97 common targets of patchouli oil for IBD treatment. GO enrichment analysis yielded 53 items. Eighteen items were obtained by KEGG enrichment analysis, involving cAMP signaling pathway, Notch signaling pathway, adhesion connection, Th17 cell differentiation and other signaling pathways. Molecular docking showed that the selected active components of patchouli oil had good binding activity with the targets. Differentially expressed genes were enriched in inflammatory pathways such as Toll-like receptors, JAK-STAT and NF-κB signaling pathways. q-PCR showed that patchouli oil, patchouli alcohol, pogostone can reduce the mRNA levels of cytokines (TNF-α, IL-1β, IL-6, and IL-23) and up-regulate the mRNA levels of tight junction proteins (occludin and claudin-1) in the inflammatory model of NCM460 normal colon epithelial cells. Patchouli alcohol can significantly reduce the levels of TNF-α, IL-6, and IL-1β inflammatory factors in RAW264.7 macrophages induced by LPS. This study revealed the multi-component, multi-target and multi-pathway of patchouli oil, and confirms the anti-inflammatory effect of patchouli oil and its main components in the inflammatory cell model in vitro and the protection of intestinal epithelial barrier integrity function, which provides a theoretical basis for further elucidating the mechanism of patchouli oil in the treatment of IBD.

     

/

返回文章
返回